urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2024-12-4-14-22urovest-916Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESДлина CAG-тринуклеотидного повтора гена рецептора андрогенов влияет на функцию эндотелия у мужчин с гипогонадизмом и сахарным диабетом 2 типаAndrogen receptor gene CAG-trinucleotide repeat length affects function of endothelium in men with hypogonadism and type 2 diabetes mellitushttps://orcid.org/0000-0003-0284-295XХрипунИ. А.KhripunI. A.

Хрипун Ирина Алексеевна — д-р мед. наук, доцент.

Ростов-на-Дону

Irina A. Khripun — Dr.Sc.(Med), Assoc. Prof. (Docent).

Rostov-on-Don

khripun.irina@gmail.comhttps://orcid.org/0000-0003-1958-9858ИсмаиловР. С.IsmailovR. S.

Исмаилов Руслан Самедович — канд. мед. наук.

Ростов-на-Дону

Ruslan S. Ismailov — Cand.Sc.(Med).

Rostov-on-Don

dr.ruslan.ismailov@gmail.comhttps://orcid.org/0000-0003-0674-9429БелоусовИ. И.BelousovI. I.

Белоусов Игорь Иванович — д-р мед. наук, доцент.

Ростов-на-Дону

Igor I. Belousov — Dr.Sc.(Med), Assoc.Prof. (Docent).

Rostov-on-Don

belrost_dept@mail.ruhttps://orcid.org/0000-0002-2954-842XИбишевХ. С.IbishevKh. S.

Ибишев Халид Сулейманович — д-р мед. наук, профессор.

Ростов-на-Дону

Khalid S. Ibishev — Dr.Sc.(Med), Full Prof.

Rostov-on-Don

ibishev22@mail.ruhttps://orcid.org/0000-0002-1710-0169КоганМ. И.KoganM. I.

Коган Михаил Иосифович — д-р. мед. наук, профессор, заслуженный деятель науки РФ.

Ростов-на-Дону

Mikhail I. Kogan — Dr.Sc.(Med), Full Prof., Hons.Sci. of the Russian Federation.

Rostov-on-Don

dept_kogan@mail.ruРостовский государственный медицинский университетРоссияRostov State Medical UniversityRussian Federation2024060920241241422Copyright © Хрипун И.А., Исмаилов Р.С., Белоусов И.И., Ибишев Х.С., Коган М.И., 20242024Хрипун И.А., Исмаилов Р.С., Белоусов И.И., Ибишев Х.С., Коган М.И.Khripun I.A., Ismailov R.S., Belousov I.I., Ibishev K.S., Kogan M.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/916Введение

Введение. Влияние длины числа CAG-повторов в гене андрогенового рецептора (nCAG AР) на эндотелиальную дисфункцию (ЭДФ) в настоящее время недостаточно изучено.

Цель исследования

Цель исследования. Оценить взаимосвязь между nCAG AР и динамикой биохимических и ультразвуковых маркеров ЭДФ у мужчин с функциональным гипогонадизмом и сахарным диабетом 2-го типа (СД2Т), получающих тестостерон-заместительную терапию (ТЗТ).

Материалы и методы

Материалы и методы. В исследование включены 45 гипогонадальных мужчин с СД2Т, получающих заместительную терапию тестостероном в течение 1 года. У пациентов определяли параметры углеводного и липидного обмена; общий и свободный Т; глобулин, связывающий половые гормоны; биохимические маркеры ЭДФ (NO, eNOS3, эндотелин) и nCAG АР; вазореактивность плечевой артерии. Пациенты были разделены на 3 группы: I группа — 9 мужчин с nCAG AР < 19; II группа — 27 мужчин с nCAG AР > 19 – 24; III группа — 9 мужчин с nCAG AР > 24.

Результаты

Результаты. Пациенты с nCAG AР < 19 демонстрировали в 2 раза большее и более быстрое увеличение вазореактивности плечевой артерии на ТЗТ по сравнению с пациентами с nCAG АР 19 – 24 и в 3 раза больше, чем мужчины с nCAG АР >24 (p < 0,05). Пациенты с nCAG АР < 19 также продемонстрировали наиболее выраженное повышение уровня NO и eNOS3 при проведении ТЗТ по сравнению с мужчинами с nCAG AР > 24. У пациентов с nCAG AР < 19 наблюдалось наиболее выраженное снижение веса, окружности талии и HbA1c на фоне терапии по сравнению с другими пациентами (p < 0,05).

Выводы

Выводы. Длина nCAG АР существенно влияет на ответ на терапию у мужчин с гипогонадизмом и СД2Т. Наиболее значительные улучшения наблюдаются у пациентов с короткой длиной nCAG АР.

Introduction

Introduction. The influence of the length of the number of CAG repeats in the androgen receptor gene (nCAG AR) on endothelial dysfunction (EnD) is currently understudied.

Objective

Objective. The study aimed to evaluate the relationship between the nCAG AR and the dynamics of biochemical and ultrasound markers of EnD in men with functional hypogonadism and type 2 diabetes mellitus (T2DM) receiving testosterone replacement therapy (TRT).

Materials & methods

Materials & methods. This study included 45 hypogonadal men with T2DM, receiving TRT for 1 year. Patients were assessed for carbohydrate and lipid metabolism parameters; total and free T; sex hormone-binding globulin; biochemical markers of EnD (NO, eNOS3, endothelin) and the nCAG AR; brachial artery (BA) vasoreactivity. Patients were divided into 3 groups: group I — 9 men with nCAG AR < 19; group II — 27 men with nCAG AR > 19 – 24; and group III — 9 men with nCAG AR >24.

Results

Results. Patients with nCAG AR < 19 exhibited a 2-fold greater and faster increase in BA vasoreactivity on TRT compared to patients with nCAG AR 19-24 and 3-fold greater than men with nCAG AR >24 (p < 0.05). Patients with nCAG AR < 19 also demonstrated the most pronounced rise in NO and eNOS3 on TRT compared to men with nCAG AR > 24. Patients with nCAG AR < 19 experienced the most pronounced decreases in weight, waist circumference, and HbA1c on TRT compared to other patients (p < 0.05).

Conclusion

Conclusion. The nCAG AR length significantly affects the response to TRT in men with hypogonadism and T2DM. The most significant improvements are seen in patients with short nCAG AR.

гипогонадизмандрогеновые рецепторысахарный диабет 2 типатестостерон-заместительная терапияCAG-повторэндотелийдисфункция эндотелияожирениеhypogonadismandrogen receptorstype 2 diabetes mellitustestosterone replacement therapyCAG repeatendotheliumendothelial dysfunctionobesityИсследование выполнено при поддержке некоммерческой федеральной государственной научной организации — Российского научного фонда (FundRef ID 10.13039/501100006769), грант № 14-25-00052.The research was supported by the non-commercial federal state scientific organization — the Russian Science Foundation (FundRef ID 10.13039/501100006769), under grant No. 14-25-00052.ReferencesPrice MA, Alvarado BE, Rosendaal NTA, Câmara SMA, Pirkle CM, Velez MP. Early and surgical menopause associated with higher Framingham Risk Scores for cardiovascular disease in the Canadian Longitudinal Study on Aging. Menopause. 2021;28(5):484-90. DOI: 10.1097/GME.0000000000001729Price MA, Alvarado BE, Rosendaal NTA, Câmara SMA, Pirkle CM, Velez MP. Early and surgical menopause associated with higher Framingham Risk Scores for cardiovascular disease in the Canadian Longitudinal Study on Aging. Menopause. 2021;28(5):484-90. DOI: 10.1097/GME.0000000000001729Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589-98. DOI: 10.1210/jcem.87.2.8201Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589-98. DOI: 10.1210/jcem.87.2.8201Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-9. DOI: 10.1111/j.1742-1241.2006.00992.xMulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-9. DOI: 10.1111/j.1742-1241.2006.00992.xBoden WE, Miller MG, McBride R, Harvey C, Snabes MC, Schmidt J, McGovern ME, Fleg JL, Desvigne-Nickens P, Anderson T, Kashyap M, Probstfield JL.Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease. Am Heart J. 2020;224:65-76. DOI: 10.1016/j.ahj.2020.03.016Boden WE, Miller MG, McBride R, Harvey C, Snabes MC, Schmidt J, McGovern ME, Fleg JL, Desvigne-Nickens P, Anderson T, Kashyap M, Probstfield JL.Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease. Am Heart J. 2020;224:65-76. DOI: 10.1016/j.ahj.2020.03.016Islam RM, Bell RJ, Handelsman DJ, McNeil JJ, Nelson MR, Reid CM, Tonkin AM, Wolfe RS, Woods RL, Davis SR. Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. Lancet Healthy Longev. 2022;3(2):e109-e118. DOI: 10.1016/S2666-7568(22)00001-0Islam RM, Bell RJ, Handelsman DJ, McNeil JJ, Nelson MR, Reid CM, Tonkin AM, Wolfe RS, Woods RL, Davis SR. Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. Lancet Healthy Longev. 2022;3(2):e109-e118. DOI: 10.1016/S2666-7568(22)00001-0Mederos MA, Bernie AM, Scovell JM, Ramasamy R. Can Serum Testosterone Be Used as a Marker of Overall Health? Rev Urol. 2015;17(4):226-30. PMCID: PMC473566Mederos MA, Bernie AM, Scovell JM, Ramasamy R. Can Serum Testosterone Be Used as a Marker of Overall Health? Rev Urol. 2015;17(4):226-30. PMCID: PMC473566Kirby M, Hackett G, Ramachandran S. Testosterone and the Heart. Eur Cardiol. 2019;14(2):103-10. DOI: 10.15420/ecr.2019.13.1Kirby M, Hackett G, Ramachandran S. Testosterone and the Heart. Eur Cardiol. 2019;14(2):103-10. DOI: 10.15420/ecr.2019.13.1Veerasamy M, Bagnall A, Neely D, Allen J, Sinclair H, Kunadian V. Endothelial dysfunction and coronary artery disease: a state-of-the-art review. Cardiol Rev. 2015;23(3):119-29. DOI: 10.1097/CRD.0000000000000047Veerasamy M, Bagnall A, Neely D, Allen J, Sinclair H, Kunadian V. Endothelial dysfunction and coronary artery disease: a state-of-the-art review. Cardiol Rev. 2015;23(3):119-29. DOI: 10.1097/CRD.0000000000000047Khripun IA, Vorobyev SV, Morgunov MN, Kogan MI. Endothelial function in men with type 2 diabetes without clinical signs of cardiovascular disease. Diabetes mellitus. 2016;19(5):383-7. DOI: 10.14341/DM8017Khripun IA, Vorobyev SV, Morgunov MN, Kogan MI. Endothelial function in men with type 2 diabetes without clinical signs of cardiovascular disease. Diabetes mellitus. 2016;19(5):383-7. DOI: 10.14341/DM8017Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes. 2017;9(5):434-49. DOI: 10.1111/1753-0407.12521Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes. 2017;9(5):434-49. DOI: 10.1111/1753-0407.12521Cyr AR, Huckaby LV, Shiva SS, Zuckerbraun BS. Nitric oxide and endothelial dysfunction. Crit Care Clin. 2020;36(2):307-21. DOI: 10.1016/j.ccc.2019.12.009Cyr AR, Huckaby LV, Shiva SS, Zuckerbraun BS. Nitric oxide and endothelial dysfunction. Crit Care Clin. 2020;36(2):307-21. DOI: 10.1016/j.ccc.2019.12.009Dubsky M, Veleba J, Sojakova D, Marhefkova N, Fejfarova V, Jude EB. Endothelial dysfunction in diabetes mellitus: new insights. Int J Mol Sci. 2023;24(13):10705. DOI: 10.3390/ijms241310705Dubsky M, Veleba J, Sojakova D, Marhefkova N, Fejfarova V, Jude EB. Endothelial dysfunction in diabetes mellitus: new insights. Int J Mol Sci. 2023;24(13):10705. DOI: 10.3390/ijms241310705Lorigo M, Mariana M, Lemos MC, Cairrao E. Vascular mechanisms of testosterone: the nongenomic point of view. J Steroid Biochem Mol Biol. 2020;196:105496. DOI: 10.1016/j.jsbmb.2019.105496Lorigo M, Mariana M, Lemos MC, Cairrao E. Vascular mechanisms of testosterone: the nongenomic point of view. J Steroid Biochem Mol Biol. 2020;196:105496. DOI: 10.1016/j.jsbmb.2019.105496Hotta Y, Kataoka T, Kimura K. Testosterone deficiency and endothelial dysfunction: nitric oxide, asymmetric dimethylarginine, and endothelial progenitor cells. Sex Med Rev. 2019;7(4):661-68. DOI: 10.1016/j.sxmr.2019.02.005Hotta Y, Kataoka T, Kimura K. Testosterone deficiency and endothelial dysfunction: nitric oxide, asymmetric dimethylarginine, and endothelial progenitor cells. Sex Med Rev. 2019;7(4):661-68. DOI: 10.1016/j.sxmr.2019.02.005Sansone A, Rastrelli G, Cignarelli A, de Rocco Ponce M, Condorelli RA, Giannetta E, Maseroli E, Pinto S, Salzano C, Santi D. Effect of treatment with testosterone on endothelial function in hypogonadal men: a systematic review and meta-analysis. Int J Impot Res. 2020;32(4):379-86. DOI: 10.1038/s41443-019-0163-6Sansone A, Rastrelli G, Cignarelli A, de Rocco Ponce M, Condorelli RA, Giannetta E, Maseroli E, Pinto S, Salzano C, Santi D. Effect of treatment with testosterone on endothelial function in hypogonadal men: a systematic review and meta-analysis. Int J Impot Res. 2020;32(4):379-86. DOI: 10.1038/s41443-019-0163-6Online Mendelian Inheritance in Man® (OMIM®). OMIM® Database [Internet]. *313700 Androgen receptor (AR) gene-phenotype relationships. Baltimore (MD), the USA: McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine. ©1966 – 2023. [cited 2022 Oct 17]. Available from: https://www.omim.org/entry/313700.Online Mendelian Inheritance in Man® (OMIM®). OMIM® Database [Internet]. *313700 Androgen receptor (AR) gene-phenotype relationships. Baltimore (MD), the USA: McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine. ©1966 – 2023. [cited 2022 Oct 17]. Available from: https://www.omim.org/entry/313700.Gerald T, Raj G. Testosterone and the androgen receptor. Urol Clin North Am. 2022;49(4):603-14. DOI: 10.1016/j.ucl.2022.07.004Gerald T, Raj G. Testosterone and the androgen receptor. Urol Clin North Am. 2022;49(4):603-14. DOI: 10.1016/j.ucl.2022.07.004Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells. 2020;9(12):2653. DOI: 10.3390/cells9122653Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells. 2020;9(12):2653. DOI: 10.3390/cells9122653, Walker WH. Androgen actions in the testis and the regulation of spermatogenesis. ADV Exp Med Biol. 2021;1288:175-203. DOI: 10.1007/978-3-030-77779-1_9, Walker WH. Androgen actions in the testis and the regulation of spermatogenesis. ADV Exp Med Biol. 2021;1288:175-203. DOI: 10.1007/978-3-030-77779-1_9McEwan IJ, Brinkmann AO. Androgen physiology: receptor and metabolic disorders. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. editor(s). Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2021.McEwan IJ, Brinkmann AO. Androgen physiology: receptor and metabolic disorders. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. editor(s). Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2021.Zitzmann M, Brune M, Kornmann B, Gromoll J, von Eckardstein S, von Eckardstein A, Nieschlag E. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasore-activity. J Clin Endocrinol Metab. 2001;86(10):4867-73. DOI: 10.1210/jcem.86.10.7889Zitzmann M, Brune M, Kornmann B, Gromoll J, von Eckardstein S, von Eckardstein A, Nieschlag E. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasore-activity. J Clin Endocrinol Metab. 2001;86(10):4867-73. DOI: 10.1210/jcem.86.10.7889Khripun IA, Vorobyev SV, Kogan MI. Association of the polymorphism in the androgen receptor gene and endothelial function in men with type 2 diabetes. Diabetes mellitus. 2015;18(4):35-40. DOI: 10.14341/DM7622Khripun IA, Vorobyev SV, Kogan MI. Association of the polymorphism in the androgen receptor gene and endothelial function in men with type 2 diabetes. Diabetes mellitus. 2015;18(4):35-40. DOI: 10.14341/DM7622Stanworth RD, Akhtar S, Channer KS, Jones TH. The role of androgen receptor CAG repeats polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 substudy. Eur J Endocrinol. 2013;170(2):193-200. DOI: 10.1530/EJE-13-0703Stanworth RD, Akhtar S, Channer KS, Jones TH. The role of androgen receptor CAG repeats polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 substudy. Eur J Endocrinol. 2013;170(2):193-200. DOI: 10.1530/EJE-13-0703Khripun IA, Morgunov MN, Vorobyev SV, Terentiev VP, Kogan MI. Endothelial dysfuncton and 2 type diabetes: novel markers for earlier diagnostics. Cardiovascular Therapy and Prevention. 2016;15(5):59-63. DOI: 10.15829/1728-8800-2016-5-59-63Khripun IA, Morgunov MN, Vorobyev SV, Terentiev VP, Kogan MI. Endothelial dysfuncton and 2 type diabetes: novel markers for earlier diagnostics. Cardiovascular Therapy and Prevention. 2016;15(5):59-63. DOI: 10.15829/1728-8800-2016-5-59-63Heald AH, Yadegar Far G, Livingston M, Fachim H, Lunt M, Narayanan RP, Siddals K, Moreno G, Jones R, Malipatil N, Rutter M, Gibson M, Donn R, Hackett G, Jones H. Androgen receptor-reduced sensitivity is associated with increased mortality and poorer glycemia in men with type 2 diabetes mellitus: a prospective cohort study. Cardiovasc Endocrinol Metab. 2020;10(1):37-44. DOI: 10.1097/XCE.0000000000000230Heald AH, Yadegar Far G, Livingston M, Fachim H, Lunt M, Narayanan RP, Siddals K, Moreno G, Jones R, Malipatil N, Rutter M, Gibson M, Donn R, Hackett G, Jones H. Androgen receptor-reduced sensitivity is associated with increased mortality and poorer glycemia in men with type 2 diabetes mellitus: a prospective cohort study. Cardiovasc Endocrinol Metab. 2020;10(1):37-44. DOI: 10.1097/XCE.0000000000000230Möhlig M, Arafat AM, Osterhoff MA, Isken F, Weickert MO, Spranger J, Pfeiffer AF, Schöfl, C. Androgen receptor CAG repeat length polymorphism modifies the impact of testosterone on insulin sensitivity in men. European journal of endocrinology. 2011;164(6):1013-8. DOI: 10.1530/EJE-10-1022Möhlig M, Arafat AM, Osterhoff MA, Isken F, Weickert MO, Spranger J, Pfeiffer AF, Schöfl, C. Androgen receptor CAG repeat length polymorphism modifies the impact of testosterone on insulin sensitivity in men. European journal of endocrinology. 2011;164(6):1013-8. DOI: 10.1530/EJE-10-1022Malavige LS, Jayawickrama S, Ranasinghe P, Levy JC. Androgen receptor CAG repeat polymorphism is not associated with insulin resistance and diabetes among South Asian males. BMC Res Notes. 2017;10(1):685. DOI: 10.1186/s13104-017-3035-5Malavige LS, Jayawickrama S, Ranasinghe P, Levy JC. Androgen receptor CAG repeat polymorphism is not associated with insulin resistance and diabetes among South Asian males. BMC Res Notes. 2017;10(1):685. DOI: 10.1186/s13104-017-3035-5Yang D, Tian J, Zhang X, Yu J, Li S, Wang Z, Ma Y, Liu L, Huang Q, Ma R, Wang J, Li X, Jiang M. The polymorphic CAG repeats in exon 1 of androgen receptor is associated with level of HDL cholesterol and hypertension in Chinese middle-aged and elderly men. Clin Endocrinol (Oxf). 2017;87(1):29-34. DOI: 10.1111/cen.13326Yang D, Tian J, Zhang X, Yu J, Li S, Wang Z, Ma Y, Liu L, Huang Q, Ma R, Wang J, Li X, Jiang M. The polymorphic CAG repeats in exon 1 of androgen receptor is associated with level of HDL cholesterol and hypertension in Chinese middle-aged and elderly men. Clin Endocrinol (Oxf). 2017;87(1):29-34. DOI: 10.1111/cen.13326Khripun IА, Vorobyev SV. Endothelial function status in hypogonadal men. Diabetes Mellitus. 2021;24(5):440-7. DOI: 10.14341/DM12780Khripun IА, Vorobyev SV. Endothelial function status in hypogonadal men. Diabetes Mellitus. 2021;24(5):440-7. DOI: 10.14341/DM12780

The authors declare that there are no conflicts of interest present.